Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights

Mar 22

Brad Good is a Circle Platinum Squarespace expert and Authorized Trainer who has built on the platform since 2008, with more than 1,900 sites to his name. He makes Language Switch, a multilingual plugin for Squarespace 7.1, and writes the guides on this site.

http://www.bradgood.net

89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints

Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights

89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints

ASLAN Pharmaceuticals Announces $20m Private Placement Led by BVF Partners L.P. With The Potential to Receive up to an Additional $80m